A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an ...

Dexcom announced the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes will ...

Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next ...

The Fitbit Charge 6 is the first real implementation of Google services into a fitness tracker since Google bought Fitbit.

People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for ...

Dexcom (NSDQ:DXCM) announced today that the FDA cleared its Smart Basal CGM-integrated basal insulin dosing optimizer.

The S&P 500 SPX has risen 14.5% this year through Friday. All price changes in this article exclude dividends. Through Friday, 57% of stocks in the S&P 500 were up for 2025.

Masimo beat analysts’ revenue expectations by 0.6% last quarter, reporting revenues of $370.9 million, up 7.9% year on year.

Oppenheimer analyst Suraj Kalia maintained a Buy rating on Nyxoah today and set a price target of $13.00. Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ...

Recently, multiple class action lawsuits were filed against DexCom, Inc. after reports surfaced alleging the company made unauthorized design changes to its G6 and G7 continuous glucose monitoring ...

DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.

The Paramount and Skydance merger, which was announced in 2024, was officially completed in August 2025. The company’s Q3 ...